APA

Crommentuijn M. H., Kantar R., Noske D. P., Vandertop W. P., Badr C. E., Würdinger T., Maguire C. A. & Tannous B. A. (20160706). Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. : Molecular therapy oncolytics.

Chicago

Crommentuijn Matheus Hw, Kantar Rami, Noske David P, Vandertop W Peter, Badr Christian E, Würdinger Thomas, Maguire Casey A and Tannous Bakhos A. 20160706. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. : Molecular therapy oncolytics.

Harvard

Crommentuijn M. H., Kantar R., Noske D. P., Vandertop W. P., Badr C. E., Würdinger T., Maguire C. A. and Tannous B. A. (20160706). Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. : Molecular therapy oncolytics.

MLA

Crommentuijn Matheus Hw, Kantar Rami, Noske David P, Vandertop W Peter, Badr Christian E, Würdinger Thomas, Maguire Casey A and Tannous Bakhos A. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. : Molecular therapy oncolytics. 20160706.